Joeri L Aerts
Overview
Explore the profile of Joeri L Aerts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
van den Ham H, Cooper J, Tomasik J, Bahn S, Aerts J, Osterhaus A, et al.
PLoS One
. 2018 Feb;
13(2):e0192278.
PMID: 29389978
Objectives: To characterize the host response to dendritic cell-based immunotherapy and subsequent combined antiretroviral therapy (cART) interruption in HIV-1-infected individuals at the plasma protein level. Design: An autologous dendritic cell...
22.
De Munck J, Binks A, McNeish I, Aerts J
J Leukoc Biol
. 2017 Jul;
102(3):631-643.
PMID: 28720686
Our understanding of the mechanisms responsible for cancer development has increased enormously over the last decades. However, for many cancers, this has not been translated into a significant improvement in...
23.
Ren Z, Aerts J, Vandenplas H, Wang J, Gorbenko O, Chen J, et al.
Cell Death Dis
. 2016 Dec;
7(12):e2560.
PMID: 28005077
Signal transducer and activator of transcription 5 (STAT5) and nucleophosmin (NPM1) are critical regulators of multiple biological and pathological processes. Although a reciprocal regulatory relationship was established between STAT5A and...
24.
Du Four S, Maenhout S, Niclou S, Thielemans K, Neyns B, Aerts J
Am J Cancer Res
. 2016 Dec;
6(11):2514-2531.
PMID: 27904768
Melanoma brain metastases (MBM) occur in 10% to 50% of melanoma patients. They are often associated with a high morbidity and despite the improvements in the treatment of advanced melanoma,...
25.
Guardo A, Joe P, Miralles L, Bargallo M, Mothe B, Krasniqi A, et al.
AIDS
. 2016 Sep;
31(3):321-332.
PMID: 27677160
Background: The development of a prophylactic vaccine against HIV-1 has so far not been successful. Therefore, attention has shifted more and more toward the development of novel therapeutic vaccines. Here,...
26.
Du Four S, Maenhout S, Benteyn D, De Keersmaecker B, Duerinck J, Thielemans K, et al.
Cancer Immunol Immunother
. 2016 Apr;
65(6):727-40.
PMID: 27098427
Background: Recurrent glioblastoma is associated with a poor overall survival. Antiangiogenic therapy results in a high tumor response rate but has limited impact on survival. Immunotherapy has emerged as an...
27.
Bialkowski L, van Weijnen A, Van der Jeught K, Renmans D, Daszkiewicz L, Heirman C, et al.
Sci Rep
. 2016 Mar;
6:22509.
PMID: 26931556
The lack of appropriate mouse models is likely one of the reasons of a limited translational success rate of therapeutic vaccines against cervical cancer, as rapidly growing ectopic tumours are...
28.
Liefferinge J, Bentea E, Demuyser T, Albertini G, Follin-Arbelet V, Holmseth S, et al.
J Comp Neurol
. 2015 Oct;
524(5):1015-32.
PMID: 26494316
The cystine/glutamate antiporter or system Xc- exchanges cystine for glutamate, thereby supporting intracellular glutathione synthesis and nonvesicular glutamate release. The role of system Xc- in neurological disorders can be dual...
29.
Onyema O, Njemini R, Forti L, Bautmans I, Aerts J, Waele M, et al.
Arch Gerontol Geriatr
. 2015 Aug;
61(3):494-502.
PMID: 26277688
Background: During organismal aging, human T-cells shift towards less functional phenotypes, often called senescent cells. As these cells have not been well characterized, we aimed to relate surface markers of...
30.
Du Four S, Maenhout S, De Pierre K, Renmans D, Niclou S, Thielemans K, et al.
Oncoimmunology
. 2015 Jul;
4(4):e998107.
PMID: 26137411
Melanoma patients are at a high risk of developing brain metastases, which are strongly vascularized and therefore have a significant risk of spontaneous bleeding. VEGF not only plays a role...